title: Acute effects of prostaglandin E1 and E2 on vascular reactivity and blood flow in situ in the chick chorioallantoic membrane.
abstract: The chick chorioallantoic membrane (CAM) subserves gas exchange in the developing embryo and shell-less culture affords a unique opportunity for direct observations over time of individual blood vessels to pharmacologic interventions. We tested a number of lipids including prostaglandins PGE(1&2) for vascular effects and signaling in the CAM. Application of PGE(1&2) induced a decrease in the diameter of large blood vessels and a concentration-dependent, localized, reversible loss of blood flow through small vessels. The loss of flow was also mimicked by misoprostol, an agonist for 3 of 4 known PGE receptors, EP(2-4), and by U46619, a thromboxane mimetic. Selective receptor antagonists for EP(3) and thromboxane each partially blocked the response. This is a first report of the effects of prostaglandins on vasoreactivity in the CAM. Our model allows the unique ability to examine simultaneous responses of large and small vessels in real time and in vivo.
authors.affiliation: Division of Pulmonary and Critical Care, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226.
authors.forename: D R
authors.initials: DR
authors.lastname: Harland
authors.affiliation: Division of Pulmonary and Critical Care, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226.
authors.forename: L D
authors.initials: LD
authors.lastname: Lorenz
authors.affiliation: Division of Pulmonary and Critical Care, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226.
authors.forename: K
authors.initials: K
authors.lastname: Fay
authors.affiliation: Division of Pulmonary and Critical Care, Department of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226.|Clement J. Zablocki VA Medical Center, Milwaukee WI 53295.
authors.forename: B E
authors.initials: BE
authors.lastname: Dunn
authors.affiliation: Division of Pulmonary and Critical Care, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226.
authors.forename: S K
authors.initials: SK
authors.lastname: Gruenloh
authors.affiliation: Division of Pulmonary and Critical Care, Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226.
authors.forename: J
authors.initials: J
authors.lastname: Narayanan
authors.affiliation: Division of Pulmonary and Critical Care, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226.|Clement J. Zablocki VA Medical Center, Milwaukee WI 53295.
authors.forename: E R
authors.initials: ER
authors.lastname: Jacobs
authors.affiliation: Division of Pulmonary and Critical Care, Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI 53226.
authors.forename: M
authors.initials: M
authors.lastname: Medhora
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000527:Alprostadil / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D001713:Biphenyl Compounds / Q000494:pharmacology; D001808:Blood Vessels / Q000187:drug effects / Q000502:physiology; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002642:Chick Embryo; D049033:Chorioallantoic Membrane / Q000098:blood supply / Q000187:drug effects* / Q000378:metabolism; D012531:Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide / Q000494:pharmacology; D015232:Dinoprostone / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004958:Estradiol / Q000494:pharmacology; D004967:Estrogens / Q000494:pharmacology; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines / Q000494:pharmacology; D008861:Microsomes / Q000187:drug effects / Q000378:metabolism; D016595:Misoprostol / Q000494:pharmacology; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D051381:Rats; D011982:Receptors, Prostaglandin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D017482:Receptors, Thromboxane / Q000819:agonists / Q000037:antagonists & inhibitors / Q000378:metabolism; D014661:Vasoconstriction / Q000187:drug effects; D014662:Vasoconstrictor Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D044004:Xanthones / Q000494:pharmacology; D017962:alpha-Linolenic Acid / Q000494:pharmacology
chemical_list: D001713:Biphenyl Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D004967:Estrogens; D005231:Fatty Acids, Unsaturated; D006834:Hydrazines; D011448:Prostaglandin Antagonists; D011982:Receptors, Prostaglandin; D017482:Receptors, Thromboxane; D014662:Vasoconstrictor Agents; D044004:Xanthones; D016595:Misoprostol; D017962:alpha-Linolenic Acid; D012531:Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide; C053876:6-isopropoxy-9-oxoxanthene-2-carboxylic acid; D004958:Estradiol; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; C046926:AH 23848; C045749:SQ 29548; D000527:Alprostadil; D015232:Dinoprostone